SEARCH

SEARCH BY CITATION

References

  • 1
    Olshansky SJ, Passaro DJ, Hershow RC, Layden J, Carnes BA, Brody J, et al. A potential decline in life expectancy in the United States in the 21st century. N Engl J Med 2005; 352: 11381145.
  • 2
    Mokdad AH, Ford ES, Bowman BA, Dietz WH, Vinicor F, Bales VS, et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 2003; 289: 7679.
  • 3
    Flegal KM, Carroll MD, Kuczmarski RJ, Johnson CL. Overweight and obesity in the United States: prevalence and trends, 1960-1994. Int J Obes Relat Metab Disord 1998; 22: 3947.
  • 4
    Gastrointestinal surgery for severe obesity. NIH consensus development conference, March 25-27, 1991. Nutrition 1996; 12: 397404.
  • 5
    Sanyal AJ, Campbell-Sargent C, Mirshahi F, Rizzo WB, Contos MJ, Sterling RK, et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001; 120: 11831192.
  • 6
    Marchesini G, Forlani G. NASH: from liver diseases to metabolic disorders and back to clinical hepatology. HEPATOLOGY 2002; 35: 497499.
  • 7
    Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999; 94: 24672474.
    Direct Link:
  • 8
    Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. HEPATOLOGY 2003; 37: 12021219.
  • 9
    Bacon BR, Farahvash MJ, Janney CG, Neuschwander-Tetri BA. Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology 1994; 107: 11031109.
  • 10
    Mofrad P, Contos MJ, Haque M, Sargeant C, Fisher RA, Luketic VA, et al. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. HEPATOLOGY 2003; 37: 12861292.
  • 11
    McCullough AJ. The clinical features, diagnosis and natural history of nonalcoholic fatty liver disease. Clin Liver Dis 2004; 8: 521533, viii.
  • 12
    Prati D, Taioli E, Zanella A, Della Torre E, Butelli S, Del Vecchio E, et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels [Comment]. Ann Intern Med 2002; 137: 110.
  • 13
    Abrams GA, Kunde SS, Lazenby AJ, Clements RH. Portal fibrosis and hepatic steatosis in morbidly obese subjects: a spectrum of nonalcoholic fatty liver disease. HEPATOLOGY 2004; 40: 47583.
  • 14
    Expert Panel on Detection E, Treatment of High Blood Cholesterol in A. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) [Comment]. JAMA 2001; 285: 24862497.
  • 15
    Colman P, Thomas D, Zimmet P, Welborne T, Garcia-Webb P, Moore M. New classification and criteria for diagnosis of diabetes mellitus. MJA 1999; 170: 375378.
  • 16
    Kleiner DE, Brunt EM, Van Natta ML, Behling C, Contos MJ, Cummings DE, et al. Design and validation of a histologic scoring system for nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) [Abstract]. HEPATOLOGY 2003; 38(Suppl): 160A.
  • 17
    Rej R. Aspartate aminotransferase activity and isoenzyme proportions in human liver tissues. Clin Chem 1978; 19711979.
  • 18
    Helfgott SM, Karlson E, Beckman E. Misinterpretation of serum transaminase elevation in “occult” myositis. Am J Med 1993; 95: 447449.
  • 19
    Nathwani RA, Pais S, Reynolds TB, Kaplowitz N. Serum alanine aminotransferase in skeletal muscle diseases. HEPATOLOGY 2005; 41: 380382.
  • 20
    Kallie L, Hahn A, Roder VZ. Correlation between histological findings and serum transaminase values in chronic diseases of liver. Acta Med Scand 1964; 175: 4556.
  • 21
    Angulo P, Keach JC, Batts KP, Lindor KD. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. HEPATOLOGY 1999; 30: 13561362.
  • 22
    Ruhl CE, Everhart JE. Determinants of the association of overweight with elevated serum alanine aminotransferase activity in the United States [see Comment]. Gastroenterology 2003; 124: 7179.
  • 23
    Piton A, Poynard T, Imbert-Bismut F, Khalil L, Delattre J, Pelissier E, et al. Factors associated with serum alanine transaminase activity in healthy subjects: consequences for the definition of normal values, for selection of blood donors, and for patients with chronic hepatitis C. MULTIVIRC Group. HEPATOLOGY 1998; 27: 12131219.
  • 24
    Sanyal AJ. AGA technical review on nonalcoholic fatty liver disease. Gastroenterology 2002; 123: 17051725.